YHC 2129
Alternative Names: YHC-2129Latest Information Update: 09 Jun 2021
At a glance
- Originator Yuhan
- Class Anorectics; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Obesity
Most Recent Events
- 01 Jun 2021 YHC 2129 is available for licensing as of 01 Jun 2021. http://eng.yuhan.co.kr/Rnd/Vision/PipeLine/
- 31 May 2021 Early research in Obesity in South Korea (unspecified route) before May 2021 (Yuhan pipeline, May 2021)